GBMA publishes information resources on biosimilars for consumers and carers

Biosimilars/General | Posted 13/11/2020 post-comment0 Post your comment

The Generic and Biosimilar Medicines Association (GBMA), the representative body of generic and biosimilar medicine suppliers in Australia, has recently published information resources for consumers and carers on biosimilars.

Educate Yourself V13H02

The GBMA has published a fact sheet providing information about the biosimilars of trastuzumab on the Pharmaceutical Benefits Scheme (PBS). The document outlines the trastuzumab biosimilars currently listed on the PBS (Trazimera®, Ogivri®, Herzuma®, Kanjinti® and Ontruzant®) and explains the process behind brand choice and brand substitution. It also explains the important role that biosimilar medicines play in the Australian healthcare system and provides links to further information.

GBMA Education, the educational arm of GBMA, has published several resources for consumers and carers about biosimilars. Brochures and fact sheets provide consumers and carers with the essentials on biosimilar medicines including an explanation of what they are, their regulation in Australia, and their beneficial role in the Australian healthcare system. The website now also features answers to the most frequently asked questions on biosimilar medicines, as well as links to recommended websites for further information including the PBS, the Therapeutic Goods Administration, and the Australian Government Department of Health.

Related articles
Biosimilar Awareness Week in Australia

GBMA publishes quarterly review of biosimilar literature

New Information on biosimilars from Australia and the US

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Biosimilars approved in Chile
ANAMED V21K19LT
Biosimilars/General Posted 19/11/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010